8% EBIT on beat

Q1'24: Better than feared

Strong start in Q1

Beat on sales and EBITDA

Tough quarter, but Q1 is seasonally small

A tad softer growth and profitability in Q1

10% adj. EBITA beat, good organic growth

Michelin : Start to the year broadly in line

>Q1 sales in line, volumes down sharply, price/mix still positive - Yesterday after trading, Michelin reported Q1 2024 sales of € 6,642m, down 5% (-3% at constant exchange rates), broadly in line with expectations (€ 6,679m, ODDO BHF € 6,613m). As expected, volumes were down at the start of the year (-4.1%, consensus -3.4%), even though they already showed a clear sequential improvement (-7.4% in Q4 2023), while the price/mix component remained robust (+0.7% vs consen...

Alan Allman Associates : Résultats 2023 mitigés (MOA solide, bottom-li...

>Résultats 2023 : bonne tenue de la MOA mais bottom-line en baisse - AAA a dévoilé hier ses résultats 2023. Pour un CA (déjà publié) de 365.6 M€, en croissance de 14% dont ~1% org d’après nos calculs, le ROA (équivalent EBITDA) ressort à 35.7 M€, légèrement supérieur à notre attente (vs ODDO BHF 34.9 M€). La MOA s’affiche ainsi à 9.8%, quasiment stable y-o-y (-20 pb), une performance honorable dans un contexte de marché moins favorable. Cela tient, selon nous, au posi...

Adyen Q1 trading update offers no surprise

Adyen reported robust net revenue growth in Q1 2024 at +21% Y/Y, bang in line with market expectations. The unchanged guidance (low-to-high twenties' growth / >50% EBITDA margin in FY2026e) and macroeconomic environment do not call for an upward estimates revision: we stick to our +22% growth fo

GlucoTrack Inc: 1 director

A director at GlucoTrack Inc bought 182,540 shares at 1.260USD and the significance rating of the trade was 50/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearl...

Orange : Equilibrium to be restored. Downgrade to Neutral

>France: market in need of rebalancing and the risk of a return of Altice France - Orange’s Q1 2024 results are a reminder of the market’s current disequilibrium: Iliad and Bouygues are capturing 80% of revenue growth on the market (vs Orange ~20% excluding wholesale which is down), including 100% of net internet growth (Orange 0%) and 80% of net growth in mobile contracts (Orange ~20% - cf. page 1). Admittedly, the fall in Orange’s customer base seems limited to 1% p...

HighCo : Un début d’année supérieur aux attentes, mais prudence de mis...

>MB T1 stable à 18.9 M€ (vs 17.6 M€e) - Au titre du T1 2024, HighCo a publié hier soir une Marge Brute stable à 18.9 M€ (+0.5%), alors que nous attendions une baisse de 6% à 17.6 M€. Cet écart provient essentiellement d’une performance meilleure qu’attendu du pôle Activation qui compense totalement la baisse des activités Mobile et Régie & Conseil/Retail. Dans le détail : 1/ le pôle Activation ressort en progression de 12.8% bénéficiant de la forte hausse des volumes ...

Ipsen : Feedback from Q1 2024 webcast

>Slower growth over the coming quarters? - Highlights from yesterday’s meeting:1/ Q1 was a good quarter, but growth in Q1 (+13% cc) seems unlikely to be extrapolated: i/ new generic versions of Somatuline are set to reach Europe and North America in H2 2024/early 2025, ii/ Cabometyx benefited from a cut-off effect, resulting in a favourable cumulative impact of =€ 20me in Q1.Management remains optimistic about Dysport (market share gains and indication exten...

Lectra : No rebound in orders yet but signs remain encouraging

>Bottom line below expectations but solid FCF generation - Lectra has reported Q1 revenue of € 129.6m, just above our estimate of € 128.2m, up 5% year-on-year including Launchmetrics (down 2% like-for-like). Unsurprisingly, revenue from new systems fell by 11% year-on-year, while recurring revenue remained favourable, up 14% year-on-year (up 5% like-for-like). Recurring EBITDA came to € 21.1m, reflecting a 30 bp improvement in EBITDA margin despite the dilutive imp...